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1. INTRODUCTION 
The design of an oral controlled drug delivery system (DDS) should be primarily aimed 
at achieving more predictable and increased bioavailability of drugs. However, the development 
process is precluded by several physiological difficulties, such as an inability to restrain and 
localize the DDS within desired regions of the gastrointestinal (GI) tract and the highly variable 
nature of gastric emptying process. It can be anticipated that, depending upon the physiological 
state of the subject and the design of pharmaceutical formulation, the emptying process can last 
from a few minutes to 12 hours (hr). This variability in turn may lead to unpredictable 
bioavailability and times to achieve peak plasma levels, since the majority of drugs are 
preferentially absorbed in the upper part of the small intestine. Furthermore, the relatively brief 
gastric emptying time (GET) in humans, which normally averages 2–3 hr through the major 
absorption zone (stomach or upper part of the intestine), can result in incomplete drug release 
from  the DDS leading to diminished efficacy of the administered dose. Thus, control of 
placement of a DDS in a specific region of the GI tract offers numerous advantages, especially 
for drugs exhibiting an absorption window in the GI tract or drugs with a stability problem. 
Overall, the intimate contact of the DDS with the absorbing membrane has the potential to 
maximize drug absorption and may also influence the rate of drug absorption. These 
considerations have led to the development of oral controlled-release (CR) dosage forms 
possessing gastric retention capabilities.
1
 
Gastro retentive systems can remain in the gastric region for several hours and hence 
significantly prolong the gastric residence time of drugs. Prolonged gastric retention improves 
bioavailability, reduces drug waste, and improves solubility for drugs that are less soluble in a 
high pH environment. It has applications also for local drug delivery to the stomach and 
proximal small intestines. Gastro retention helps to provide better availability of new products 
with new therapeutic possibilities and substantial benefits for patients.
2
 
1.1 Basic Gastrointestinal Tract Physiology: 
1 
It is well recognized that the stomach may be used as a ‘depot’ for sustained-release (SR) 
dosage forms, both in human and veterinary applications. The stomach is anatomically divided 
into three parts: fundus, body, and antrum (or pylorus). The proximal stomach, made up of the 
fundus and body regions, serves as a reservoir for ingested materials while the distal region 
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(antrum) is the major site of mixing motions, acting as a pump to accomplish gastric emptying. 
The process of gastric emptying occurs both during fasting and fed states; however, the pattern 
of motility differs markedly in the two states. In the fasted state, it is characterized by an inter-
digestive series of electrical events which cycle both through the stomach and small intestine 
every 2–3 hr. This activity is called the inter-digestive myoelectric cycle or MMC, which is often 
divided into four consecutive phases.  
 Phase I is a quiescent period lasting from 40 to 60 min with rare contractions.  
 Phase II is a period of similar duration consisting of intermittent action potentials and 
contractions that gradually increase in intensity and frequency as the phase progresses.  
 Phase III is a short period of intense, large regular contractions lasting from 4 to 6 min. 
It is this phase, which gives the cycle the term ‘housekeeper’ wave, since it serves to 
sweep undigested materials out of the stomach and down the small intestine. As phase III 
of one cycle reaches the end of the small intestine, phase III of the next cycle begins in 
the duodenum.  
 Phase IV is a brief transitional phase that occurs between phase III and phase I of two 
consecutive cycles. In the fed state, the gastric emptying rate is slowed since the onset of 
MMC is delayed. In other words, feeding results in a lag time prior to the onset of gastric 
emptying. Overall, the relatively brief GI transit time of most drug products, which is 
approximately 8–12 h, impedes the formulation of a once daily dosage form for most 
drugs. These problems can be exacerbated by alteration in gastric emptying that occur 
due to factors such as age, race, sex, and disease states, as they may seriously affect the 
release of a drug from the DDS. It is, therefore, desirable to have a CR product that 
exhibits an extended GI residence and a drug release profile independent of patient 
related variables. 
 
1.2 Factors Affecting Gastric Retention: 
3
 
 Density – GRT is a function of dosage form buoyancy that is dependent on the density. 
 Size – dosage form units with a diameter of more than 7.5mm are reported to have an 
increased GRT compared with those having diameter of 9.9mm. 
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 Shape of dosage form – tetrahedron and ring shaped devices with a flexural modulus of 
48 and 22.5 kilo pounds per square inch are reported to have better GRT ≈ 90% to 100% 
retention at 24 hr compared with other shapes. 
 Fed or unfed state – under fasting conditions, the GI motility is characterized by periods 
of strong motor activity or MMC that occurs every 1.5 to 2 hr. The MMC sweeps 
undigested material from the end if the timing of administration of the formulation 
coincides with that of the MMC, the GRT of the unit can be expected to be very short. 
However, in the fed state, MMC is delayed and GRT is considerably longer. 
 Nature of meal – feeding of indigestible polymers or fatty acid salts can change the 
motility pattern of the stomach to a fed state, thus decreasing the gastric emptying rate and 
prolonging drug release. 
 Caloric content – GRT can be increased by 4 to 10 hr with a meal that is high in proteins 
and fats. 
 Frequency of feed – the GRT can increase by over 400 minutes when successive meals 
are given compared with a single meal due to the low frequency of MMC. 
 Gender – mean ambulatory GRT in males (3.4±0.6 hr) is less compared with their age 
and race matched female counterparts (4.6±1.2 hr), regardless of the weight, height and 
body surface). 
 Age – Elderly people, especially those over 70, have a significantly longer GRT. 
 Posture – GRT can vary between supine and upright ambulatory states of the patient. 
 Concomitant drug administration – anticholinergics like atropine and propantheline, 
opiates like codeine and prokinetic agents like metoclopramide and cisapride. 
 Biological factors – diabetes and Crohn’s disease, etc. 
 1.3 Gastroretentive forms: 
4, 10, 11
 
1. Floating systems 
2.  High density systems 
3. Expandable systems 
4. Superporous hydrogels 
5. Mucoadhesive or bioadhesive systems 
6. Magnetic systems 
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1. Floating systems 
 These have a bulk density lower than the gastric content. They remain buoyant in the 
stomach for a prolonged period of time, with the potential for continuous release of drug. 
Eventually, the residual system is emptied from the stomach. Gastric emptying is much more 
rapid in the fasting state and floating systems rely heavily on the presence of food to retard 
emptying and provide sufficient liquid for effective buoyancy. 
2. High density systems 
      Gastric contents have a density close to water (1.004 g/cm
3
). When the patient is upright 
small high-density pellets sink to the bottom of the stomach where they become entrapped in the 
folds of the antrum and withstand the peristaltic waves of the stomach wall. A density close to 
2.5 g /cm
3
 seems to be necessary for significant prolongation of gastric residence time and 
barium sulphate, zinc oxide, iron powder, titanium dioxide are used as excipients. 
                                
Fig:1 Schematic localization of an intragastric floating system and a high-density System in 
the stomach 
3. Expandable systems 
A dosage form in the stomach will withstand gastric transit if it is bigger than the pyloric 
sphincter. However, the dosage form must be small enough to be swallowed, and must not cause 
gastric obstruction either singly or by accumulation. Thus, three configurations are required: a 
small configuration for oral intake, an expanded gastroretentive form and a final small form 
enabling evacuation following drug release. Unfoldable and swellable systems have been 
investigated. Unfoldable systems are made of biodegradable polymers. The concept is to make a 
carrier, such as a capsule, incorporating a compressed system which extends in the stomach. 
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4. Hydrogel systems 
Although these are swellable systems, they differ sufficiently from the conventional types 
to warrant separate classification. With pore size ranging between 10 nm and 10 Am, absorption 
of water by conventional hydrogel is a very slow process and several hours may be needed to 
reach an equilibrium state during which premature evacuation of the dosage form may occur. 
Superporous hydrogels, average pore size >100 Am, swell to equilibrium size within a minute, 
due to rapid water uptake by capillary wetting through numerous interconnected open pores  
Moreover, they swell to a large size and are intended to have sufficient mechanical strength to 
withstand pressure by gastric contraction. 
 
 
Fig: 2 i) On the left, superporous hydrogel in its dry (a) and water-swollen (b) state. ii) 
On the right, schematic illustration of the transit of superporous hydrogel. 
5. Mucoadhesive or bioadhesive systems: 
  The basis of mucoadhesion is that a dosage form can stick to the mucosal surface by 
different mechanisms. Different theories are invoked to explain these mechanisms. Firstly, the 
electronic theory proposes attractive electrostatic forces between the glycoprotein mucin network 
and the bioadhesive material. Secondly, the adsorption theory suggests that bioadhesion is due to 
secondary forces such as Van der Waals forces and hydrogen bonding. The wetting theory is 
based on the ability of bioadhesive polymers to spread and develop intimate contact with the 
mucus layers, and finally, the diffusion theory proposes physical entanglement of mucin strands 
and the flexible polymer chains, or an interpenetration of mucin strands into the porous structure 
of the polymer substrate. Materials commonly used for bioadhesion are poly(acrylic acid) 
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(Carbopol\, polycarbophil), chitosan, Gantrez\ (Polymethyl vinyl ether/maleic anhydride 
copolymers), cholestyramine, tragacanth, sodium alginate, HPMC, sephadex, sucralfate, 
polyethylene glycol, dextran, poly(alkyl cyanoacrylate) and polylactic acid. 
 
6.  Magnetic systems: 
  This system is based on a simple idea: the dosage form contains a small internal magnet, 
and a magnet placed on the abdomen over the position of the stomach. Although these systems 
seem to work, the external magnet must be positioned with a degree of precision that might 
compromise patient compliance. 
1.4 Technological developments in FDDS: 
1, 5, 6, 9         
     
   Based on mechanism of buoyancy, two distinctly different technologies have been 
utilized in the development of FDDS, which are effervescent system and non effervescent 
system. 
A. Effervescent system: 
Effervescent system include use of gas generating agents, carbonate(sodium bicarbonate) 
and other organic acids (citric acid and tartaric acid) to produce carbon dioxide(CO2) gas, thus 
reducing the density of the system and making it to float on the gastric fluid. The effervescent 
further classified into two types. 
(Ι)  Gas Generating Systems: 
1.   Intra Gastric Single Layer Floating Tablet: 
      These are formulated by the CO2 generating agents and the drug within matrix tablet. 
These have a bulk density lower than gastric fluids and therefore remain floating in the stomach 
unflattering the gastric emptying rate for a prolonged period. The drug is slowly released at a 
desired rate from the floating system and after the complete release the residual system is 
expelled from the stomach. This leads to an increase in GRT and better control over fluctuations 
in plasma drug concentrations. 
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2.  Intra Gastric Bilayered Floating Tablets: 
       These are also compressed tablets and contain two layers for: 
        Immediate release layer and Sustained release layer 
                                                                        
Fig: 3 Intra Gastric Bilayered Floating Tablets 
3.  Multiple Unit type floating pills:  
  These systems consist of sustained release pills as ‘seeds’ surrounded by double layers. 
The inner layer consists of effervescent agents while the outer layer is of swellable membrane 
layer. When the system is immersed in dissolution medium at body temperature it sinks at once 
and then forms swllowen pills like balloon and float as the density decreases. 
                     
Fig: 4 A multiple-unit oral floating dosage system. 
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Fig: 5 Stages of floating mechanism: (A) penetration of water; (B) generation of CO2 and 
floating; (C) dissolution of drug. Key: (a) conventional SR pills; (b) effervescent layer; (c) 
swellable layer; (d) expanded swellable membrane layer; (e) surface of water in the beaker 
 
ΙΙ.  Volatile liquid/ vacuum containing systems: 
1. Intragastric Floating Gastroretentive Drug Delivery System: 
 These systems can be made to float in the stomach because of floatation chamber, which 
may be a vacuum or filled with air or a harmless gas, while drug reservoir is encapsulated inside 
a microporous compartment. 
  
 
 
  
                                   
 
 
Fig6: Intragastric floating drug delivery device 
 
2. Inflatable Gastroretentive Delivery System: 
 In these systems an inflatable chamber is incorporated, which contains liquid that gasifies 
at body temperature to cause the chamber to inflate in the stomach. These systems are fabricated 
by loading the inflatable chamber with a drug reservoir, impregnated polymeric matrix, and then 
encapsulated in a gelatin capsule. After oral administration of the capsule dissolve to release the 
drug reservoir together with the inflatable chamber. The inflatable chamber automatically 
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inflates and retains the drug reservoir compartment in floating position. The drug continuously 
released from the reservoir into the gastric fluid. 
 
Fig: 7 Gastro-inflatable drug delivery device 
3.  Intragastric Osmotically Controlled Drug Delivery System: 
 It is comprised of an osmotic pressure controlled drug delivery device and an inflatable 
floating support in a biodegradable capsule. In the stomach, capsule quickly disintegrates to 
release the intragastric osmotically controlled drug delivery device. The inflatable support inside 
forms a deformable hollow polymeric bag that contains a liquid that gasifies at body temperature 
to inflate the bag. The osmotic pressure controlled drug delivery device consists of two 
components; drug reservoir compartment and an osmotically active compartment. 
 The drug reservoir compartment is enclosed by a pressure responsive collapsible bag, 
which is impermeable to vapour and liquid and has a drug delivery orifice. The osmotically 
active compartment contains an osmotically active salt and is enclosed within a semipermeable 
housing. In the stomach, the water in the GI fluid is continuously absorbed through the 
semipermeable membrane into osmotically active salt. An osmotic pressure is thus created which 
acts on the collapsible bag and turns in forces the drug reservoir compartment reduce its volume 
and activate the drug reservoir compartment to reduce its volume and activate the drug release in 
solution form through the delivery orifice. 
 
Fig: 8 Intragastric osmotic controlled drug delivery system 
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B. Non Effervescent Systems:
 2, 7 
The non effervescent FDDS is based on mechanism of swelling of polymer or 
bioadhesion to mucosal layer in GI tract. The most commonly used excipients in non-
effervescent FDDS are gel forming or highly swellable cellulose type hydrocolloids, 
polysaccharides and matrix forming materials such as polycarbonates, polyacrylates, 
polymethaacrylates, polystyrenes etc. and bioadhesive polymer such as chitosan and carbopol.  
                          
   Fig: 9 Principle of hydrodynamically balanced system. 
The various types of systems are: 
 Single Layer Floating Tablets: 
   They are formed by intimate mixing of drug with a gel forming hydrocolloid, which 
swells in contact with gastric fluid and maintain bulk density of less than unity. The air trapped 
by the swollen polymer confers buoyancy to these dosage forms. 
 Alginate Beads:                                                                                                    
   Multi unit floating dosage forms were developed from freeze dried calcium alginate. 
Spherical beads of approximately 2.5mm diameter can be prepared by dropping sodium alginate 
into aqueous solution of calcium chloride, causing precipitation of calcium alginate leading to 
formation of porous system, which can maintain a floating force for over 12 hr. These floating 
beads gave a prolonged residence time of more than 5.5 hr. 
 Hollow Microspheres: 
  Multiple-unit hollow microspheres by emulsion solvent diffusion technique were 
prepared with drug and acrylic polymer. These were dissolved in an ethanol-dichloromethane 
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mixture, and poured into an aqueous solution of PVA with stirring to form emulsion droplets. 
The rate of drug release in micro balloons was controlled by changing the polymer to drug ratio. 
Microballons were floatable in vitro for 12 hours when immersed in aqueous media. Radio 
graphical studies proved that microballons orally administered to humans were dispersed in the 
upper part of the stomach and retained there for 3 hours against peristaltic movements. 
1.5 Advantages and Disadvantages of FDDS
7, 10 
Advantages of FDDS: 
 Drugs that act locally in the stomach e.g. antacids, antibiotics for microbial based 
ulcer, etc. 
 Drugs that are absorbed primarily in the stomach e.g. Albuterol 
 Drugs those are poorly soluble in alkaline pH. 
 Drugs that have narrow absorption window for absorption of the drugs which are 
absorbed from the proximal part of the small intestine. E.g. riboflavin, Levodopa, 
PABA. 
 Drugs that degrade in colon e.g. Captopril, Metoprolol. 
Disadvantages of FDDS: 
 High variability in gastric emptying time due to variations in emptying process. 
 Drugs that cause irritation and leisions to gastric mucosa and unstable in gastric fluid 
cannot be formulated as FDDS 
 Drugs with unpredictable bioavailability, minimum effective concentration are 
achieved slowly. 
 Gastric retention is achieved by many factors such as gastric motility, pH, and 
presence of food. These factors are never constant hence the buoyancy cannot be 
predicted. 
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                          Table N0.1: MARKETED PRODUCT OF FDDS:  
 
Sr. 
No. 
Brand Name Delivery 
system 
Drug (dose) Company, 
Country 
1        Madopar Floating, CR 
capsule 
Levodopa (100 
mg), Benserazide 
(25 mg) 
Roche 
Products, USA 
2 Valrelease Floating 
capsule 
Diazepam (15 mg) Hoffmann-
LaRoche, USA 
3 Liquid 
Gaviscon 
Effervescent 
floating liquid 
alginate 
preparation 
Al hydroxide 
(95mg),                      
Mg carbonate     
(358 mg) 
Glaxo Smith-
Kline, India 
4 Topalkan Floating liquid 
alginate 
preparation 
Al-Mg antacid Pierre Fabre 
Drug, France 
5 Almagate Flot 
Coat 
Floating 
dosage form 
Al-Mg antacid ---------- 
6 Conviron Colloidal gel 
forming FDDS 
Ferrous sulphate Ranbaxy, India 
7 Cifran OD Gas-generating 
floating form 
Ciprvenlafaxine hcl  
(1g) 
Ranbaxy, India 
8 Cytotec Bilayer floating 
capsule 
Misoprostol 
(100mcg/200mcg 
Pharmacia, 
USA 
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Depression: 
12, 13
 
 It is an affective disorder which refers to a change in mood state. It is characterized by 
symptoms like loss of interest, suicidal thoughts, low energy change in appetite and 
sleep. 
 One in four men and one in six men will suffer from depression at some point in their 
lives. It is a complicated illness which involves a number of contributing factors – genes, 
environment, diet, lifestyle, psychology and personality. 
 For treatment of depression based on patient individual symptoms various 
antidepressants are used include MAO’s, TCA’s, SSRI’s which are associated with 
major side effects. 
 Venlafaxine HCl is a novel antidepressant of serotonin and noradrenaline reuptake 
inhibitor with prominent side effects are sweating, anxiety, dizziness and impotence. But 
doesn’t interact with adrenergic, cholinergic, histaminic receptors thus having 
 No sedative action   
 Fast onset of action 
 Safer in overdose 
 No usual side effects 
 
  
 
 
Chapter ii 
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2. REVIEW OF LITERATURE ON FLOATING DRUG DELIVERY SYSTEM 
Anil G et al., (2011), prepared a controlled release tablet of Venlafaxine HCl, which releases the 
drug in a sustained manner over a period of 12 hrs. Three different viscosity grades of HPMC 
namely K4M, K15M, K100M were used for the tablets. The tablets were prepared by direct 
compression method and then evaluated. A combination of HPMC k100M was found to achieve 
optimum in-vitro buoyancy.
16 
 
Senthil A et al., (2011), formulated the mucoadhesive microspheres of Venlafaxine HCl by 
single emulsification phase separation technique using different volumes of glutaraldehyde as 
crosslinking agent. The optimized formulation was selected based on the percentage of 
mucoadhesion and sphericity of microspheres.the optimized formulation exhibited a high drug 
entrapment efficiency of 70% and a swelling index 1.57%.Mucoadhesion after 1 hr was 91% and 
the drug release was also sustained for more than 12hrs. As the concentration of the 
glutaraldehyde increased, the mucoadhesiveness decreases and there was no significant effect in 
time.
17
  
Pare. A et al., (2011), developed amlodipine besylate effervescent floating tablets by using 
hydrophilic polymers HPMC and cabopol934 along with effervescent agents like sodium 
bicarbonate and citric acid. It was found that carbopol has a negative effect on floating behavior 
but it was found that carbopol has a negative effect on floating behavior but it was used only for 
the drug release retardant charecteristics.
18 
 
Sreekanth S.K. et al., (2010), prepared floating matrix tablets using HPMC K100M as a 
polymer and sodium bicarbonate as gas generating agent. The compressed were then evaluated 
and there was no interaction between drug polymer and excepients, it was found out by IR 
studies. The in-vitro drug release study indicate that the release of the drug depends on the 
proportion of the polymer present in formulation .As the polymer ratio increases the release rate 
of the drug is prolonged.
19
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Subash C et al., (2011), designed a controlled release floating tablet of Diltiazem HCl using 
Xanthan gum as a polymer. It was noted that the drug release from the prepared tablets was 
found to vary with varying concentration of the polymer. From the study it was concluded that 
floating tablets can be prepared by using Xanthan gum as a carrier.
20 
 
Bagherwal A et al., (2010), have formulated the floating tablets of Ciprofloxacin HCl with 
HPMC and carbomer in different proportions (4%, 8%,9 %)  by direct compression technique. 
The formulations were then evaluated and the mechanism of drug release with all the 
formulations was dominantly diffusion and followed zero order kinetics. The results revealed the 
drug polymer ratio showed greater drug release than other formulations.
21 
 
Raja et al., (2011), prepared a gastro retentive floating tablets of Glipizide by using two different 
polymers HPMC K4M and HPMC K15M at different concentration. It was found that as the 
concentration of polymer increased, floating lag time decreased. Use of high viscosity polymer 
can also decreases the floating lag time and viscosity of the polymer should directly proportional 
relationship with swelling characteristics of tablets.
22 
 
Kotwal K et al., (2008), prepared intragastric buoyant tablets of Amoxicillin trihydrate by using 
different grades of HPMC polymer as gelling agent. It was found that hardness of the tablet will 
affect the buoyancy characteristics of the dosage form. The in-vitro release study was concluded 
that amoxicillin releases from the tablet followed peppa’s model with non-fickian diffusion.23   
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Patel VM et al., (2009), were prepared gastroretentive tablets of Verapamil HCl by using 
different hydrocolloid polymer including carbopol (CP 934; CP 940), 
hydroxypropaxymethylcellulose (HPMC K4M; HPMC K15M; HPMC E15) and xanthan gum by 
direct compression technology. The selected tablets containing xanthan gum released 
approximately 97.89% drug in 24 hours in-vitro dissolution study, while buoyancy lag time was 
24.6 seconds and the tablet remained buoyant for more than 24 hours. 
24
 
 
 
Jaimini M et al., (2007), were formulated Famotidine floating tablets by using different grades 
of methocel (K100, K15M), PVP K-30, gas generating agent sodium bicarbonate and citric acid. 
The floating tablets were evaluated for physicochemical characteristics. All the prepared batches 
showed good in vitro buoyancy. The effect of citric acid on drug release profile and floating 
properties was investigated. The tablets with methocel K100 were found to be float for longer 
duration as compared with formulation containing methocel K15.
25 
 
 
Prabhu P et al., (2008), were prepared a gastro retentive floating controlled drug delivery 
system containing Glipizide in the form of tablet. Ten formulations containing retardant 
materials such as HPMC4K and eudragit RS100, alkalizing agent sodium bicarbonate and other 
release promoters such as sodium lauryl sulphate and polyvinyl pyrrolidone were used. Tablets 
remained buoyant over 8 hours in the release medium, and the amount of sodium bicarbonate 
found to be significant for not only to remaining buoyant without causing disintegration of the 
tablet. Further the selected best formulations were compared with the marketed sustained release 
product and found to be comparable release of the drug. All the formulations exhibited diffusion 
dominated drug release.
26
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Deshmukh VN et al., (2009), were prepared theophylline anhydrous bioadhesive tablets by 
using different natural polymers such as xanthan gum, locust bean gum, guar gum, karaya gum 
and their combinations were used to formulate matrix tablets. The bioadhesive strength of the 
tablets were measured as the force of detachment against the porcine gastric mucosa. The 
combination of karaya gum: guar gum (6:4) Tablet showed greater biodhesive strength as 
compared with single gum and other gum combination tablets. Karaya gum: guar gum loaded 
tablets were not discharged from the mucous membrane and were dissolved in gastric fluid. An 
increase in the gum concentration increases the drug profile beyond 12 hours whereas there is no 
significant effect of gum concentration on bioadhesive strength of the tablet.
27 
 
 
Rahman et al., (2006), designed the bilayer floating tablets of captopril using HPMC-K15 M, 
K4M, PVP-K30 and Carbopol 934p alone or in combination with the drug in release layer and 
HPMC K grade, effervescent mixture of citric acid and sodium bi carbonate in the floating 
layer. It was found that 95 % of drug released in 24 hrs, tablet remained floatable throughout all 
studies and release followed the Higuchi model. In vivo X-ray studies indicated that placebo 
formulation containing barium sulphate in the release layer significantly increased the gastric 
residence time.
28 
 
 
Gambhire  et al., (2007),  Studied on Oral floating matrix tablets of Diltizem Hydrochloride by 
using  Methocel K-100M CR, Compritol 888 ATO, Sodium bicarbonate, succinic acid and 
concluded that the effervescent-based floating drug delivery is a promising approach to achieve 
in vitro buoyancy by using gel-forming polymer methocel K 100 CR and gas generating agent 
sodium bicarbonate.  A high level of both Methocel K-100M CR and compritol 888 ATO favors 
the preparation of the floating controlled release of DTZ tablets.
29 
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Arza RAK et al., (2009), were prepared Swellable and floating gastroretentive ciprofloxacin 
hydrochloride tablet by using a combination of hydrophilic polymer 
(hydroxypropylmethylcellulose), swelling agent (crosspovidone, sodium starch glycolate, and 
croscarmelose sodium) and effervescent substance (sodium bicarbonate). A combination of 
HPMC K100, crosspovidone, and sodium carbonate shows the good swelling, drug release, and 
floating character than the marketed product of ciprofloxacin hydrochloride CIFRAN OD.
30
 
 
 
Prajapati ST et al., (2009), were prepared Floating matrix tablets of domeperidone were 
prepared by wet granulation technique, using polymer such as HPMC K4M, carbopol 934P and 
sodium alginate either alone or in combination, and other standard excipients. Tablets were 
evaluated for physical characteristics and in vitro release characteristics for 24 hours. Floating 
matrix tablet based on combination of three polymers exhibited desired floating and prolonged 
drug release for 24 hours. Carbopols loading showed negative effect on floating properties but 
were found helpful to control the release rate of drug.
31 
 
 
Sungthongjeen S et al., (2008), were designed Floating multi-layer coated tablets of 
theophylline based on gas formation. The system consists of a drug containing core tablet coated 
with a protective layer (hydroxypropylmethylcellulose), a gas forming layer (sodium 
bicarbonate) and a gas-entrapped membrane, respectively. The properties of acrylic polymers 
(eudragit RL 30D, RS 30D, NE 30D) and ethyl cellulose were characterized by the puncture test 
in order to screen a suitable film for the system. Eudragit RL 30D was chosen as a gas-entrapped 
membrane due to its high flexibility and high water permeability. The obtained tablets enabled to 
float due to the CO2-gas formation and the gas entrapment by polymeric membrane.
32   
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Singh S et al., (2007), were developed floating matrix tablets of metoclopramide hydrochloride 
using the polymers such as guar gum, karaya gum, HPMC E15 alone and in combination with 
HPMC K15M (HK) and gas generating agents such as calcium carbonate and citric acid. Tablets 
with gas generating agent and with HK floated for 24 hours without complete erosion and 
showed slower drug release. This indicates that the gas forming agent contributes towards the 
initial floating of tablets and faster drug release and HK for maintaining the integrity of the 
floating matrix tablet and sustaining the drug release.
33 
 
Vinay pandit et al., (2010), designed gastro retentive form of amoxicillin trihydrate floating 
tablets. The formulations were prepared as matrix tablets in the form of non effervescent tablets 
by using various grades of HPMC. The granules were prepared by wet granulation technique and 
tablets were evaluated. The optimized formulation of amoxicillin was found to have increased 
gastric residence prolonging the release of drug with 85% of drug release in 6 hrs by diffusion. 
The mechanism of drug release was found to be diffusion and followed combination of zero 
order and first order kinetics.
34 
 
Mokhopadhayats et al., (2010), formulated floating bioadhesevie tablets of ciprofloxacin Hcl 
by direct compression technique. Tablets were prepared by using polymers like HPMC, SCMC, 
carbopol in different ratios. The effervescent base was prepared by using 1: 1 ratio of sodium 
bycarbonate and citric acid. It was observed that tablets with 5% effervescent base shows greater 
control in drug release in comparison to that of 10%.
35 
 
Atul kumar sahu et al., (2011), prepared buoyant controlled release tablet of furosemide 
containing chitosan and HPMC as a polymer and evaluated. The effect of chitosan and HPMC 
concentration on drug release kinetics and buoyancy was also determined. The in vitro drug 
release of furosemide in all the formulations was best explained by zero order equation and 
followed mechanism of non-fickian diffusion. By combining HPMC with chitosan in various 
blends, the formulation found to be more suitable for oral controlled release of furosemide.
36 
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Srinivas reddy et al., (2010), developed floating matrix tablets of captopril by using natural 
gumd like xanthine gum, karaya gum, gellan gum along with HPMC K4M, PVP K30. The 
tablets were prepared by direct compression using sodium bicarbonate as gas generating agent 
and evaluated. The linear regression analysis and model fitting showed that all this formulation 
followed Higuchi model.
37 
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                                3. DRUG AND EXCIPIENT PROFILE  
 
3.1 DRUG DATA- VENLAFAXINE HCL:
 14, 15
 
Venlafaxine HCl is a serotonin and norepinephrine reuptake inhibitors 
Molecular formula: CH27NO2 HCl 
Molecular weight:  313.87 
Structure:     
                                    
                      Fig: 10 Structure of Venlafaxine HCl 
Chemical name: (RS)-1-[2-dimethylamino-1-(4-methoxyphenyl)-ethyl]cyclohexanol 
Category: Anti-depressant 
3.1.1Physico-chemical properties: 
Description: white crystalline powder 
Standards: venlafaxine HCl contains not less than 98.5 per cent and not more than of 101.5 per 
cent , calculated on the dried basis. 
Solubility: venlafaxine HCl is considered to be soluble in aqueous solutions with pH between 2 
and 5. It is sparingly to slightly soluble in aqueous solutions with pH 7. 
Melting point:  Venlafaxine HCl melts at 207-209
0
C 
Bioavailability: 30% 
Metabolism: Hepatic 
Half life: 4hours 
Excreation: Renal 
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Mechanism of action:  
The mechanism of the antidepressant action of Venlafaxine HCl in humans is believed to 
be associated with its potentiation of neurotransmitter activity in the CNS. Preclinical studies 
have shown that Venlafaxine HCl and its active metabolite, O-desmethyl venlafaxine (ODV), are 
potent inhibitors of neuronal serotonin and norepinephrine reuptake and weak inhibitors of 
dopamine reuptake. Venlafaxine HCl and ODV have no significant affinity for muscarinic 
cholinergic, H1-histaminergic, or α1-adrenergic receptors in vitro. Pharmacologic activity at 
these receptors is hypothesized to be associated with the various anticholinergic, sedative, and 
cardiovascular effects seen with other psychotropic drugs. Venlafaxine HCl and ODV do not 
possess monoamine oxidase (MAO) inhibitory activity. 
Dosage and Administration: 
Extended release: 
Daily dose: 75-150 mg orally 
Maximum dose (moderately depressed outpatients): 225 mg/day 
Maximum dose (severely depressed inpatients): 375 mg/day 
Adverse effects:  
Suicidal thinking(suicidality), sweating, nausea, constipation, anorexia, vomiting, 
somnolence, dry mouth, dizziness, nervousness, anxiety, tremor, and blurred vision. 
Contraindications: 
Venlafaxine HCl hydrochloride tablets must not be used concomitantly in patients taking 
MAOIs or in patients who have taken MAOIs within the preceding 14 days due to the risk of 
serious, sometimes fatal, drug interactions with SNRI or SSRI treatment or with other 
serotonergic drugs. These interactions have been associated with symptoms that include tremor, 
myoclonus, diaphoresis, nausea, vomiting, flushing, dizziness, hyperthermia with features 
resembling neuroleptic malignant syndrome, seizures, rigidity, autonomic instability with 
possible rapid fluctuations of vital signs, and mental status changes that include extreme 
agitation progressing to delirium and coma. 
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3.2 POLYMER PROFILE: 
15
 
3.2.1 CARBOPOL934 
1. Nonproprietary Names: 
BP: Carbomer 
USPNF: Carbomer 
JP:  carboxyvinyl polymer 
2.  Synonyms: 
 Carboxypolymethylene , polyacrylic acid. 
3. Functional Category: 
Controlled release agent, stabilizing agent, viscosity enhancing agent, binding agent. 
4. Applications in pharmaceutical formulation or technology: 
They are used in wide range of pharmaceutical applications which provide: 
 Controlled release in tablets 
 Bioadhesion in buccal, ophthalmic, intestinal, nasal, vaginal and rectal applications. 
 Thickening at very low concentrations to produce a wide range of viscosities and flow 
properties in topical, lotions, creams and gels, oral suspensions and transdermal gel 
reservoirs. 
 Permanent suspensions of insoluble ingredients in oral suspensions and topicals. 
 Emulsifying topical oil-in-water systems permanently, even at elevated 
temperatures, with essentially no need for irritating surfactants. 
5. Description:  
It occurs as odorless, tasteless, fluffy white powder. 
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6. Structural Formula:             
 
7. Solubility:  
The Carbopol resins are hydrophilic substances that are not soluble in water. Rather, 
these polymers swell when dispersed in water forming a colloidal, mucilage-like dispersion. 
Carbopol polymers are bearing very good water sorption property. They swell in water up 
to 1000 times their original volume and 10 times their original diameter to form a gel when 
exposed to a pH environment above 4.0 to 6.0. 
 
8. Viscosity (dynamic):   
Different grades of Carbopol polymers exhibit different rheological properties, a 
reflection of the particle size, molecular weight between crosslinks (Mc), distributions of the Mc, 
and the fraction of the total units, which occur as terminal, i.e. free chain ends. The viscosity 
range of different Carbopol polymers are as follows 
S.No polymer viscosity 
1 Carbopol 934 NF 30500 – 39400 
2 Carbopol 934 p NF 29400 – 39400 
3 Carbopol  71G NF 4000 – 11000 
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3.2.2 XANTHAN GUM 
1. Nonproprietary Names: 
BP: Xanthan gum 
USPNF: Xanthani gum 
2.  Synonyms: 
Corn sugar gum; E415; Keltrol; polysaccharide B-1459; Rhodigel; Vanzan NF; Xantural 
3. Chemical Name: 
Xanthan gum 
4. Functional Category: 
Stabilizing agent; Suspending agent; Viscosity-increasing agent. 
5. Applications in pharmaceutical formulation or technology: 
Xanthan gum is widely used in oral and topical pharmaceutical formulations, cosmetics, and 
foods as a suspending and stabilizing agent. It is also used as a thickening and emulsifying agent. 
6. Description: 
  Xanthan gum occurs as a cream- or white-colored, odorless, free-flowing, fine powder. 
7. Typical properties:  
 Acidity/alkalinity: pH = 6.0–8.0 for a 1% w/v aqueous solution. 
 Melting point       : Chars at 270˚C. 
 Solubility             : practically insoluble in ethanol and ether; soluble in cold or 
                                 warm water 
8. Safety:  It is safe when up to 15grams per day are taken. It can cause some side effects such as 
intestinal gas. 
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3.2.3 HYDROXYPROPYL METHYLCELLULOSE 
1. Nonproprietary Name: 
BP: Hypromellose 
USP: Hypromellose 
2.  Synonyms: 
Hydroxy Propyl Methyl Cellulose, HPMC, Hypromellosum, Methocel, Methyl Cellulose 
Propylene Glycol Ether, Methyl Hydroxy Propyl Cellulose, Metolose, MHPC.  
3. Chemical Name:  Cellulose Hydroxy Propyl Methyl Ether 
 
4. Empirical Formula and Molecular Weight: 
The PhEur 6.3 describes hypromellose as a partlyO-methylated and O-(2-
hydroxypropylated) cellulose.  Molecular weight is approximately 10 000–1 500 000. 
5. Structural Formula:             
                                                          
 Where, R is H, CH3, or CH3CH(OH)CH2 
                                             Fig: 11 Structure of HPMC 
6. Applications in Pharmaceutical Formulation or Technology: 
HPMC is widely used in oral, ophthalmic, nasal, and topical pharmaceutical 
formulations. In oral products, hypromellose is primarily used as a tablet binder, in film-coating, 
and as a matrix for use in extended release tablet formulations. Concentrations between 2% and 
5% w/w may be used as a binder in either wet- or dry-granulation processes. High-viscosity 
grades may be used to retard the release of drugs from a matrix at levels of 10–80% w/w in 
tablets and capsules. Hypromellose is also used in liquid oral dosage forms as a suspending 
and/or thickening agent at concentrations ranging from 0.25–5.0%.  
 
 
7. Description: 
Hypromellose is an odorless and tasteless, white or creamy-white fibrous or granular 
powder. 
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8. Solubility: 
Soluble in cold water, forming a viscous colloidal solution, practically insoluble in hot 
water, chloroform, ethanol (95%), and ether, but soluble in mixtures of ethanol and 
dichloromethane, mixtures of methanol and dichloromethane. 
9. Viscosity (dynamic): 
A wide range of viscosity types are commercially available. Aqueous solutions are most 
commonly prepared. 
Typical viscosity values for 2% (w/v) aqueous solutions of methocel 
(Dow Chemical Co.) viscosities measured at 20ºC 
  
Methocel grade  
 
Viscosity(cps)  
K4 M  
 
4000  
 
K15M  
 
15000  
 
K100M  
 
100000  
 
 
10. Stability and Storage Conditions: 
Hypromellose powder should be stored in a well-closed container, in a cool, dry place. 
11. Safety: 
Hypromellose is generally regarded as a nontoxic and nonirritating material, although 
excessive oral consumption may have a laxative effect. 
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3.3. EXCIPIENT PROFILE: 
15
 
3.3.1 SODIUM BICARBONATE 
1. Nonproprietary Names: 
BP: Sodium Bicarbonate 
PhEur: Sodium Hydrogen Carbonate 
USP: Sodium Bicarbonate 
2. Synonyms: 
Baking soda, E500, Effer-Soda, Sodium acid carbonate, Sodium hydrogen carbonate. 
3. Chemical Name: Carbonic acid monosodium salt 
4. Empirical Formula and Molecular Weight: NaHCO3 and 84.01 
5. Applications in Pharmaceutical Formulation or Technology: 
Sodium bicarbonate is generally used in pharmaceutical formulations as a source of 
carbon dioxide in effervescent tablets and granules. It is also widely used to produce or maintain 
an alkaline pH in a preparation. Recently, sodium bicarbonate has been used as a gas-forming 
agent in alginate raft systems and in floating, controlled release oral dosage forms for a range of 
drugs. Therapeutically, sodium bicarbonate may be used as an antacid, and as a source of the 
bicarbonate anion in the treatment of metabolic acidosis.  
6. Descriptions: 
Sodium bicarbonate occurs as an odorless, white, crystalline powder with a saline, 
slightly alkaline taste. 
7. Stability and Storage Conditions: 
Sodium bicarbonate is stable in dry air but slowly decomposes in moist air and should 
therefore be stored in a well-closed container in a cool, dry place. 
8. Incompatibilities: 
Sodium bicarbonate reacts with acids, acidic salts, and many alkaloidal salts, with the 
evolution of carbon dioxide. Sodium bicarbonate can also intensify the darkening of salicylates.  
9. Safety: 
When used as an excipient, sodium bicarbonate is generally regarded as an essentially 
nontoxic and nonirritant material. Administration of excessive amounts of sodium bicarbonate 
may thus disturb the body’s electrolyte balance, leading to metabolic alkalosis or possibly 
sodium overload with potentially serious consequences. 
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3.3.2 MICROCRYSTALINE CELLULOSE 
1. Nonproprietary Names: 
BP: Microcrystalline Cellulose 
PhEur: Cellulose, Microcrystalline 
USP-NF: Microcrystalline Cellulose 
2. Synonyms: Avicel, cellulose gel, crystalline cellulose, E460, Emocel, Fibrocel, Tabulose, 
Vivacel.  
3. Functional Category: Tablet and Capsule diluent, suspending agent, adsorbent, tablet 
disintegrant.  
4. Applications: As a diluent in tablets (direct compression and direct compression) and capsule 
formulation. In addition to its use as a diluent, it also has some lubricant and disintegrant 
property.  
5. Description: White-colored, odourless, tasteless crystalline powder composed of porous 
particles. Available in different particle size grades which have different properties and 
applications.  
6. Solubility: Slightly soluble in 5 % w/v NaOH solution, practically insoluble in water, dilute 
acids and most organic solvents.  
7. Stability: It is a stable, though hygroscopic material.  
8. Storage conditions: The bulk material should be stored in a well-closed container in a cool 
and dry place.  
9. Incompatibilities: Incompatible with strong oxidizing agents.  
10. Safety: It is generally regarded as a nontoxic and nonirritant material. 
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3.3.4 MAGNESIUM STEARATE: 
1. Non-proprietary names: 
BP: Magnesium stearate  
JP: Magnesium stearate 
PhEur: Magnesii stearas  
USPNF: Magnesium stearate 
2. Synonyms: Magnesium octadecanoate, octadecanoic acid magnesium salt and stearic acid 
magnesium salt. 
3. Chemical name: Octadecanoic acid magnesium salt 
4. Structural formula: [CH3 (CH2)16COO] 2 Mg 
5. Molecular weight: 591.34 
6. Functional category: Tablet and capsule lubricant. 
7. Melting point: 117-150 
0
C 
 
8. Description: Magnesium stearate is a fine, white, precipitated or milled, impalpable powder 
of low bulk density, having a faint odor of stearic acid and a characteristic taste. The powder is 
greasy to touch and readily adheres to the skin. 
 
9. Solubility: It is practically insoluble in ethanol (95%), ether and water; slightly soluble in 
warm benzene and warm ethanol (95%). 
 
10. Applications: It is widely used in cosmetics, foods and pharmaceutical formulations. It is 
primarily used as a lubricant in the manufacturing of tablets and capsules, in the concentration of 
0.25-5.0%. It is also used in barrier creams. 
 
11. Stability and storage conditions: It should be stored in a well closed container in a cool, dry 
place. 
 
DRUG AND EXCIPIENT PROFILE 
 
Department of Pharmaceutics, Nandha College of Pharmacy. Page 31 
 
3.3.5 TALC 
1. Non-proprietary names: 
BP: Purified talc 
PhEur: Talcum 
USP: Talc 
2. Synonyms: Altalc, powdered talc, purified French chalk, Purtalc, soapstone, steatite and 
Superiore. 
3. Chemical name: Talc 
4. Structural formula: Mg6 (Si2O5)4(OH)4 
5. Functional Category: Anticaking agent, glidant and lubricant. 
 6. Description: 
It is a very fine, white to grayish-white, odorless, impalpable, unctuous, crystalline 
powder. It adheres readily to the skin and is soft to touch and free from grittiness. 
7. Solubility: 
It is practically insoluble in dilute acids and alkalis, organic solvents and water. 
8. Applications: 
It was once widely used in oral solid dosage formulations as a lubricant and diluent. It is 
widely used as dissolution retardant in the development of controlled release products. In topical 
preparations, it is used as a dusting powder, although it should not be used to dust surgical 
gloves. It is a natural material it may frequently contain micro-organisms and should be sterilized 
when used as a dusting powder. It is additionally used to clarify liquids and is also used mainly 
for its lubricant properties, in cosmetics and food products. 
9. Stability and storage conditions: 
It is a stable material and may be sterilized by heating at 160

C for not less than 1 hour. It 
may also be sterilized by exposure to ethylene oxide or gamma irradiation. It should be stored in 
a well closed container in a cool and dry place. 
10. Incompatibilities: 
It is incompatible with quaternary ammonium compounds. 
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4. AIM AND OBJECTIVE 
4.1 AIM OF THE WORK 
 The aim of this present work is to formulate a gastro retentive floating tablet of 
Venlafaxine HCl by direct compression method using various polymers such as Carbopol 
934, Xanthan gum,   and HPMC K-100M. 
 Venlafaxine HCl exhibits pH dependent solubility. It is more soluble in acidic pH and 
slightly soluble at neutral or alkaline condition (intestinal environment). Hence an 
attempt will be made to develop gastroretentive delivery system of Venlafaxine HCl 
which would increase the bioavailability of Venlafaxine HCl and also to reduce 
frequency of administration, thereby improving patient compliance and therapeutic 
efficacy.  
4.2 PLAN OF WORK 
1. Pre- formulation studies for possible drug or polymer interaction by IR analysis. 
2. Preparation of floating tablets by direct compression method. 
3. Evaluation of the various properties of floating tablets. 
 Evaluation of precompression parameters such as bulk density, tapped density, 
compressibility index etc. 
 Evaluation of post compression parameters like thickness, hardness, friability, drug 
content, In vitro buoyancy studies. 
4.  Drug release study using suitable in-vitro model. 
5. Carry out short term stability studies on the most satisfactory formulation. 
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5. METHODOLOGY 
5.1: INGREDIENTS USED: 
       Table No.2 
S. No. INGREDIENTS AND REAGENTS 
MANUFACTURER / 
SUPPLIERS 
1 Venlafaxine HCl Aurabindo pharma 
2 Carbopol 934p Himedia laboratories 
3 Xanthan gum Himedia laboratories 
4 HPMC K100M Aurabindo pharma 
5 Sodium bicarbonate Nice laboratories 
6 MCC S.D fine chemicals 
7 Magnesium Stearate S.D fine chemicals 
8 Talc Nice laboratories 
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 5.2 INSTRUMENTS USED:  
       Table No.3     
 
5.3 PREFORMULATION STUDIES 
38
 
Preformulation testing is an investigation of physical and chemical properties of drug 
substances alone and when combined with pharmaceutical excipients.  It is the first step in the 
rational development of dosage form. 
 
Sr. 
No. 
NAME OF INSTRUMENT MANUFACTURING COMPANY 
1. Digital Balance Shimatzu LB 300 
2. Tablet hardness tester Pfizer hardness tester 
3. Friability tester Riche Pharma 
4. Vernier Caliper Mitutoyo digimatic caliper 
5. Dissolution apparatus USP  
Electrolab tablet dissolution 
apparatus 
6. 
Double beam UV 
Spectrophotometer 
Shimatzu UV-1800 
7. Rotary tablet punching machine Cadmach 
8. pH meter Elico Ll120 
9. FT-IR Spectrophotometer KBR press model M15 
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5.3.1 Compatibility studies (Fourier Transform Infrared Spectroscopic studies)  
Table no. 4: Description and composition of formulation 
 
Procedure: 
The drug-excipient interaction study was carried out using by KBr pellet method. To 
study the compatibility of various formulation excipients with Venlafaxine HCl, solid admixtures 
were prepared by mixing the drug with each formulation excipient separately in the ration of 1:1 
and it was filled and characterized by using Fourier transform infrared spectroscopy (FT-IR). 
5.3.2 UV- Spectrum Analysis of Drug 
Venlafaxine HCl drug solution in pH 1.2(0.1N HCl) was scanned using UV-
Spectrophotometer between the range 210-400nm using pH 1.2 as blank and the range of the 
drug was found to be 224nm. 
5.4 STANDARD CURVE OF VENLAFAXINE HCL BY UV-SPECTROPHOTOMETER  
Venlafaxine HCl can be estimated spectrometrically at 224 nm as it obeys Beer’s –
Lambert’s law limit is the range of 2-20µg/ml. 
100mg of Venlafaxine HCl was dissolved in 100ml of 0.1N HCl so as to get a stock 
solution of 1000 g/ml concentration.10ml of stock solution was made to 100ml with 0.1N HCl 
thus giving a concentration of 100 g/ml. Aliquot of standard drug solution ranging from 0.2ml 
to 1ml were transferred in to 10ml volumetric flask and were diluted up to the mark with 0.1N 
HCl. Thus the final concentration ranges from 2-10 g/ml. Absorbance of each solution was 
measured at 224 nm against 0.1N HCl as a blank. A plot of concentrations of drug vs. 
absorbance was plotted. 
S. no. INGREDIENTS FUNCTIONS 
1 Venlafaxine hcl Active ingredients 
2 Carbopol Polymer 
3 Xanthan gum Polymer 
4 HPMC K-100M Polymer 
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5.5 PREPARATION OF VENLAFAXINE HCL FLOATING TABLETS.
39, 40, 41
 
Floating matrix tablet were prepared by using direct compression technique with use of 
different polymer with varying concentration(1:1,1:1.5,1:2) i.e., drug to polymer ratio  as shown 
in the above table. All polymer and drug were passed through sieve no.80 separately. Then drug 
were mixed for 10 min with polymers and other excipients in weight proportion as mentioned in 
the table. The powder blend was then lubricated by magnesium stearate and talc and this 
lubricated blend were subjected to compression into tablets using 10-mm flat-face on a 16 
stationary rotary punching tablet machine. 
Table no. 5: Composition of floating tablets of Venlafaxine HCl 
Average weight of tablets 330 mg. 
5.6    EVALUATION PARAMETERS 
44, 45
 
5.6.1 Pre Compression Parameters 
1. Bulk density (Db): 
It is the ratio of powder to bulk volume. The bulk density depends on particle size 
distribution, shape and cohesiveness of particles. Accurately weighed quantity of powder was 
carefully poured into graduated measuring cylinder through large funnel and volume was 
measured which is called initial bulk volume. Bulk density is expressed in gm/cc and is given by,             
 Db = M / Vo  Where, Db = Bulk density (gm/cc) 
                                     M =Mass of powder (g) 
                                     Vo = Bulk volume of powder (cc) 
Ingrediants(mg/tablet) F1 F2 F3 F4 F5 F6 F7 F8 F9 
Venlafaxine HCl 75 75 75 75 75 75 75 75 75 
Carbopol934 75 112.5 150 _ _ _ _ _ _ 
Xanthan gum _ _ _ 75 112.5 150 _ _ _ 
HPMC K100M _ _ _ _ _ _ 75 112.5 150 
MMC 95 57.5 20 95 57.5 20 95 57.5 20 
Sodium bicarbonate 70 70 70 70 70 70 70 70 70 
Mg stearate 5 5 5 5 5 5 5 5 5 
Talc 10 10 10 10 10 10 10 10 10 
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2. Tapped density (Dt): 
Ten grams of powder was introduced into a clean, dry 100ml measuring cylinder. The 
cylinder was then tapped 100 times from a constant height and tapped volume was read. It is 
expressed in gm/cc and is given by, 
                 Dt = M / Vt Where, Dt = Tapped density (gm/cc) 
                                              M = Mass of powder (g) 
                                              Vt = Tapped volume of powder (cc) 
3. Angle of repose (θ): 
It is defined as the maximum angle possible between the surface of pile of the powder 
and the horizontal plane. Fixed funnel method was used. A funnel was fixed with its tip at a 
given height (h), above a flat horizontal surface on which a graph paper was placed. Powder was 
carefully poured through a funnel till the apex of the conical pile just touches the tip of funnel. 
The angle of repose was then calculated using the formula, 
 θ = tan-1(h/r)        where, θ = angle of repose 
                                       h = height of pile,  
        r = radius of the base of the pile. 
 
 
Table No.6: Relation between the angle of repose (θ), and Flowability 
Angle of repose (θ) 
Flowability 
<20 Excellent 
20-30 Good 
30-40 Passable 
>40 Very poor 
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4. Carr’s Compressibility Index: 
An indirect method of measuring powder flow from bulk densities was developed by 
carr. The percentage compressibility of powder was a direct measurement of the potential 
powder arch or the bridge strength and stability. Carr’s index of each formulation was calculated 
according to equation given below: 
                           Df – Do   
%compressibility =   ----------------     ×100 
 
                       Df                Where,    Df = Tapped density                        
                             Do = Bulk density 
           
 
Table no.7   Relationship between % compressibility and Flowability 
CARR’S INDEX (%) TYPE OF FLOW 
5-12 Excellent 
12-18 Good 
18-23 Fair to passable 
23-35 Poor 
35-38 Very poor 
>40 Extremely poor 
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5.6.2: Post Compression Parameters 
1. Thickness:  
Control of physical dimension of the tablet such as thickness is essential for consumer 
acceptance and tablet uniformity. The thickness and diameter of the tablet was measured using 
vernier calipers. It is measured in mm. 
2. Hardness: 
Hardness indicates the ability of a tablet to withstand mechanical shocks while 
handling.The Monsanto hardness tester was used to determine the tablet hardness. The tablet was 
held between a fixed and moving jaw. Scale was adjusted to zero; load was gradually increased 
until the tablet fractured. The value of the load at that point gives a measure of hardness of the 
tablet. Hardness was expressed in Kg/cm
2
.Three tablets were randomly picked and hardness of 
the tablets was determined.  
3. Friability: 
Tablet strength was tested by using Roche Friabilater. 20 tablets were weighed and 
placed in the friabilator and operated at for 100 revolutions (4min), taken out and were dedusted. 
The percentage weight loss was calculated by reweighing the tablets. The % friability was then 
calculated by, 
                                     
4. Weight variation: 
Ten tablets were selected randomly from each batch were weighed individually and 
together in a single pan balance. The average weight was noted and standard deviation 
calculated. The tablet passes the test if not more than two tablets fall outside the percentage limit 
and none of the tablet differs by more than double the percentage limit. 
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Table No.8 IP standards of uniformity of weight 
Sl.No Average weight of tablet % of deviation 
1 ≤ 130 mg ±10 
2 > 130 mg to <324 mg ±7.5 
3 ≥ 324 mg ±5 
                                                                                          
Where,      PD = Percentage deviation, 
                    W avg = Average weight of tablet,  
                    W initial = individual weight of tablet.  
5. Swelling Index: 
38, 46 
Measurement of swelling rate of the floating matrix tablet was carried to gain insight the 
observed phenomenon of drug release with the rates of polymer hydration. Swelling index of the 
dosage form is conducted by using USP dissolution apparatus-II in 900 ml of 0.1N HCl which is 
maintained at 37±0.5°C, rotated at 50 rpm. At selected regular intervals, the tablet was 
withdrawn and the excess water was blotted with tissue paper and the swelling index was 
calculated using following formula. 
% Swelling Index = {(Wt) – (Wo)/ (Wo)} x 100  
Where, Wt = weight of the swollen tablet 
          Wo = initial weight of the tablet. 
 
6. Buoyancy studies: 
 The in-vitro floating behavior (buoyancy) of the tablets was determined by floating lag 
time.The tablets were placed in 100 ml beaker containing 0.1 N HCl (pH 1.2). The floating lag 
time (time taken by the tablet to reach the surface) and total floating time (floating duration of 
the tablet) were determined.  
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7. Uniformity of drug content: 
The drug content was performed to check the dose uniformity in the formulation. 
Randomly ten tablets were weighed and powered. A quantity equivalent to 100mg of 
Venlafaxine  HClwas added in to a 100ml volumetric flask and dissolved in 0.1N HCI, shaken 
for 10 minutes and made up to the volume with 0.1N HCl. After suitable dilutions the drug 
content was determined by UV spectrophotometer at 224nm again blank. 
 
8. In-Vitro release studies for floating tablets
47
 
The drug release rate was determined using USP dissolution apparatus II. Dissolution 
media was 900ml of simulated gastric fluid (pH 1.2) maintained at 37± 0.1 ˚C and stirred at 50 
rpm. Samples were withdrawn at suitable time intervals and compensated with fresh dissolution 
medium and assayed spectrophotometrically at 224nm in Shimadzu U.V. spectrophotometer. 
Samples were assayed in triplicate.  
 
9. Kinetic analysis of In-Vitro release rates of floating tablets of Venlafaxine HCl 
Several kinetic models have been proposed to describe the release charecteristics of a 
drug from matrix. The following three equations were used, because of their simplicity and 
applicability.  
 Equation 1, the zero order model (Plotted as cumulative percentage of drug Vs time). 
 Equation2, First order kinetic model (Log cumulative percent drug remaining Vs time).  
 Equation 3, Higuchi‘s square root equation (plotted as cumulative percent drug release 
Vs square root of time).  
 Equation 4, the korsmeyer peppas equation (plotted as Log cumulative percent drug 
release Vs Log time). 
To study the relese kinetics of Venlafaxin HCl the release was fitted to the above four equations.  
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Table no. 9: Mechanism of Drug Release as per Korsmeyer Equation / Peppa’s     Model 
S. No. N Value Drug release 
1. 0.45 Fickian release 
2. 0.45 <n <0.89 Non – Fickian release 
3. n> 0.89 Class II transport 
 
10. Stability studies
49 
Stability studies of pharmaceutical products were done as per ICH guidelines.  These 
studies are designed to increase the rate of chemical or physical degradation of the drug 
substance or product by using exaggerated storage conditions.  
Method: Selected formulations were stored at different storage conditions at elevated 
temperatures such as 25
o
C± 2
0
C / 60% ± 5% RH, 30
0
C ± 2
0
C / 65% ±5% RH and 40
0
C ± 2
0
C/ 
75% ± 5% RH for 90 days. The samples were withdrawn at intervals of 30 days and checked for 
physical changes, hardness, friability, drug content, floating lag time and percentage drug 
release. 
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6. RESULTS AND DISCUSSION  
 
6.1. DETERMINATION OF λmax OF Venlafaxine Hcl IN ACID BUFFER (pH 1.2) 
 
Fig12:  Spectrum of Venlafaxine HCl 
 Venlafaxine HCl drug solution in pH 1.2(0.1N HCl) was scanned using UV-
Spectrophotometer between the range 210-400nm using pH 1.2 as blank and the maximum 
absorbance (λ max) was found at 224nm. 
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6.2. CALIBRATION CURVE OF Venlafaxine HCl   
Table No.10:  Calibration curve of Venlafaxine HCl in 0.1N HCl (pH 1.2) 
Sl. No Concentration(µg/ml) Absorbance at 
224nm 
1 02 0.136 
2 04 0.305 
3 06 0.462 
4 08 0.612 
5 10 0.754 
 
Fig13: Calibration curve of  Venlafaxine HCl in 0.1N HCl (pH 1.2) 
 
From the standard curve of Venlafaxine HCl it was observed that the drug obeys Beer’s 
law in the range of 2-20µg/ml. 
 
 
y = 0.0765x - 0.0043 
R² = 0.9993 
-0.1 
0 
0.1 
0.2 
0.3 
0.4 
0.5 
0.6 
0.7 
0.8 
0 2 4 6 8 10 12 
A
b
so
rb
an
ce
 
Concentration 
RESULTS AND DISCUSSION 
 
Department of Pharmaceutics, Nandha College of Pharmacy. Page 45 
 
 6.3 FTIR STUDIES 
TABLE NO. 11 Compatibility Studies of Venlafaxine HCl with Excipients 
 
SL. 
NO 
 
Excipients 
Drug/ 
Excipients 
Ratio 
Physical 
Description 
Initial 
35
0
C ± 2
0
C  / 60% ± 5% 
RH 
1 
Week 
2 
Week 
3 
Week 
1 Venlafaxine HCl - White 
crystalline 
powder 
            
* 
           
* 
            
* 
2 Drug + 
carbopol934 
1:1 
 
White 
crystalline 
powder 
 
* 
 
* 
 
* 
3 Drug + xanthan 
gum 
1:1 White 
crystalline 
powder 
 
* 
 
* 
 
* 
4 Drug + HPMC 
k100M 
1:1 White 
crystalline 
powder 
 
* 
 
* 
 
* 
       * indicates no incompatibility. 
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   Fig14:  FTIR Spectroscopy of pure drug 
 
 
   Fig15:  FTIR Spectroscopy of Carbopol934 
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  Fig16:  FTIR Spectroscopy of Xanthan gum 
 
 
 
Fig17:  FTIR Spectroscopy of HPMC K100M 
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  Fig18:  FTIR Spectroscopy of pure drug+ Carbopol 934 
 
 
  Fig19:  FTIR Spectroscopy of pure drug+ Xanthan gum 
RESULTS AND DISCUSSION 
 
Department of Pharmaceutics, Nandha College of Pharmacy. Page 49 
 
 
  Fig20:  FTIR Spectroscopy of pure drug+ HPMC K100M 
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Table No. 12: Comparison of the peak of functional groups of Venlafaxine HCl observed in 
IR spectra of compatibility studies: 
 
 
S. No 
 
Types of 
vibrations 
 
IR 
absorption 
Ranges 
(cm
-1
) 
 
 Drug 
(cm
-1
) 
Physical mixture(drug + polymer) 
Drug              
+       
xanthan 
gum 
Drug      
+ 
carbopol 
934 
Drug                     
+   
HPMC 
K100M 
1  Aromatic   
C-H 
stretching 
3000-2850 2939.6 2936.5 2942.5 2945.4 
2 Aromatic 
C=C 
stretching 
1680-1600 1647.2 1642.9 1632.4 1648.2 
3 O-H 
stretching 
3400-3600 3349.5 3349.5 3437.2 3332.1 
4 C-O 
stretching 
1300-1000 1243.16 1245.9 1246.6 1247.2 
5 N-H 
stretching 
(1˚ & 
2˚amine) 
3500-3100 3349.5 3349.5 3437.2 3332.1 
6 C-N 
stretching 
1350-1000 1308.7 1302.9 1304.5 1302.9 
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 In order to check the integrity of the drug in the formulation, FTIR spectra of pure 
drug(Venlafaxine HCl), Carbopol 934, HPMC K100M, Xanthan gum and mixture of 
drug with the above polymers were taken and compared. The FTIR spectrum of 
Venlafaxine HCl reveal the presence of peaks at 2939.6 due to the presence of C-H 
stretching, 1647.2 due to the presence of C=C aromatic stretching, 3349.5 due to the 
presence of    O-H stretching, 1243.16 due to the presence of C-O stretching, 3349.5 due 
to the presence of N-H stretching, 1308 due to the presence of C-N stretching. 
 Major frequencies of functional groups of pure drug remain intact in powder containing 
Carbopol 934, HPMC K100M and Xanthan gum. Hence there is no major interaction 
between the drug and polymers used in the study. 
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6.4 EVALUATION PARAMETERS: 
6.4.1 Pre Compression Parameters 
Table No.13: Evaluation parameters of powder blend 
 
Formulation Angle of 
repose 
Bulk 
density(gm/cc) 
Tapped 
density(gm/cc) 
Compressibility 
index (%) 
F1 29 
0
1
l
±0.1 0.36±0.004 0.41±0.018 11.8±0.8 
F2 30
0 
3
l
±0.2 0.37±0.001 0.44±0.017 13.4±0.8 
F3 32
0
 1
l
±0.5 0.38±0.005 0.44±0.004 13.3±0.6 
F4 30
0
 6
1
±0.3 0.35±0.005 0.41±0.003 14.2±1.4 
F5 32
0
 8
1
±0.5 0.34±0.004 0.40±0.018 14.8±1.2 
F6 33
0
 8
1
±0.1 0.35±0.002 0.42±0.001 16.2±0.7 
F7 28
0 
1
1
±0.7 0.35±0.002 0.40±0.005 12.6±0.9 
F8 28
0 
5
1
±0.3 0.36±0.003 0.41±0.002 12.7±1.1 
F9 31
0 
2
1
±0.1 0.36±0.005 0.42±0.004 14.2±1.3 
 
 Floating tablets of Venlafaxine HCl was developed to increase the gastric residence time 
of the drug, so that they can be retained in the stomach for longer time and help in 
controlled release of drug up to 12 hrs. 
  Different grades of viscosities of Carbopol 934, xanthan gum, HPMC K100M polymers 
is known to be beneficial in improving floating property and release charecteristics. 
 The pre- compression parameters obtained for all formulations are tableted in the table no 
13. The value of angle of repose was found to be in the range of 28
0
1
1
 to 33
0
8
1
. This 
indicates good flow property of powder blend. Carr’s index value ranges between 11.8 to 
16.2% indicates that the powder blend have the required flow property for direct 
compression.  
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6.4.2 Post Compression Parameters: 
Table no.14: Evaluation parameters of formulations 
Formulation Thickness   
( mm) 
Hardness   
(kg/cm
2
) 
Friability        
(%) 
Average  
weight 
variation(mg) 
Drug 
content 
(%) 
F1 3.76±0.04 5.33±0.02 0.65±0.07 331.2±1.3 98.06 
F2 3.68±0.07 5.61±0.05 0.59±0.09 330.7±1.4 98.39 
F3 3.62±0.02 5.44±0.03 0.53±0.05 331.5±1.7 97.22 
F4 3.71±0.04 5.48±0.01 0.54±0.11 330.2±2.1 99.02 
F5 3.67±0.09 5.86±0.04 0.47±0.08 329.8±2.3 97.18 
F6 3.63±0.11 6.14±0.02 0.47±0.12 331.3±2.1 97.56 
F7 3.74±0.02 5.42±0.03 0.57±0.04 329.2±1.4 97.19 
F8 3.76±0.01 5.57±0.01 0.54±0.07 328.7±1.8 98.45 
F9 3.69±0.05 5.72±0.05 0.53±0.06 331.4±1.2 98.28 
 
 The floating tablets were prepared by direct compression method using the polymers 
Carbopol 934, Xanthan gum, HPMC K100M to provide sufficient drug release 
retardation and provide sufficient buoyancy to the tablets .The results have shown in the 
table no.14. 
 The prepared floating tablets were evaluated for thickness, hardness, friability, average 
weight variation, drug content, all the studies were performed in triplicates and the results 
were expressed in ± standard deviation.  
 The measured hardness for the tablets for each batch arranged between 5.33 to 6.14 
kg/cm, this ensures the good handling characteristics of all the batches. 
 The % friability was less than 1% in all the formulations ensuring that the tablets were 
mechanically stable. 
 The weight variation for different formulations was found to be 328.7 to 331.4, indicates 
consistency in each batch. 
 The drug content was found to be 97.19 to 98.45, with low standard deviation indicates 
batch to batch consistency. 
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6.5 SWELLING INDEX: 
Table no.15: Swelling index (%) of formulations 
Time  
(hrs) 
Formulations 
F1 F2 F3 F4 F5 F6 F7 F8 F9 
1 26.6 23.3 22.8 40.7 37.2 36.4 22.1 19.4 17.8 
2 43.88 39.36 41.2 73.25 74.5 68 36.5 36.1 34.7 
4 87.45 74.77 65.7 115.4 108.4 109.3 72.3 64.2 59.4 
6 123.5 121.1 114.8 140.2 132.8 130.7 112.7 98.2 89.2 
8 155.4 146.2 124.1 163.7 160.3 154.2 128.7 114.5 114.2 
10 158.8 149.7 132.8    132.3 121.1 119.5 
12 162.4 154.5 133.4    135.1 126.9 122.3 
 
             
 
                Fig21:  Graph for comparison of swelling index of all the formulation          
              Swelling index for all the formulations was carried out in the 0.1N HCl. The 
formulations showed different indices in the swelling media and it is shown in the table. Tablets 
containing carbopol934 and HPMC K100M showed maximum swelling in 12 hr with sharp 
increase up to 8 hr this may due to increased concentration of HPMC K100M which retain water 
and form thick swollen mass.  
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6.6 BUOYANCY STUDIES: 
Table no. 16: Buoyancy studies of formulations 
Formulation code Floating lag time (sec) Floating duration (hrs) 
F1 52 >12 
F2 58 10 
F3                    76 10 
F4 29 7 
F5 36 8 
F6 34 8 
F7 34 >12 
F8 32 >12 
F9 39 >12 
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Fig22:  In vitro buoyancy studies of optimized formulation 
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 The in-vitro floating behavior of the tablets was studied by placing them in beaker 
containing 0.1 N HCl (pH 1.2). The gas generating agents immediately evolves carbon 
dioxide in presence of HCl solution generating sufficient porosity which helped the 
dosage unit to float. Formulation F1-F3 prepared with carbopol934p started floating after 
52 seconds and remains buoyant for 10 hr till they were completely eroded. 
 On the other hand formulation F4-F6 prepared with Xanthan gum which shows a floating 
time of 8hrs and formulation of F7-F9 prepared with HPMC K100M show decrease in 
floating lag time to 34 seconds and increased floating duration time to >12hrs. This might 
be due to high viscosity polymer HPMC K100M maintains the integrity of the tablets for 
longer duration by reducing the effect of erosion thus resulting in increase in floating 
time. The results are shown in table no.16.Thus it can be concluded that the batch 
containing HPMC polymers showed good floating lag time and total floating time.  
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6.7 In-Vitro DRUG RELEASE STUDIES: 
 In-vitro drug release studies were carried out using USP dissolution apparatus type II at 
50 rpm. The dissolution medium consisted of 900 ml of pH 1.2 acid buffer (0.1N HCl), 
maintained at 37 + 0.5
0
C. The drug release at different time intervals was measured using an 
ultraviolet visible spectrophotometer at 224 nm.  
Table no.17: Percentage drug release of formulations 
Time 
(hrs) 
Formulations 
F1 F2 F3 F4 F5 F6 F7 F8 F9 
1 24.87 22.92 20.06 38.34 33.28 27.54 23.46 22.43 17.84 
2 36.24 33.82 29.71 52.15 45.38 38.15 36.87 31.11 24.18 
4 58.16 55.27 48.07 81.67 64.19 56.77 57.82 53.67 43.67 
6 76.08 71.18 69.18 96.44 81.23 79.26 72.09 65.28 61.08 
8 87.28 85.33 78.92 96.94 97.61 96.13 83.12 76.59 69.49 
10 94.79 91.67 86.13 97.96 97.92 98.21 94.65 88.76 83.54 
12 96.53 93.11 88.33 98.1 98.67 98.72 98.74 98.34 90.03 
 
 
   
                     Fig23:  In-vitro dissolution profile of F1 to F3 formulations. 
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                            Fig24:  In-vitro dissolution profile of F4 to F6 formulations. 
 
 
 
 
 
 
 
 
                        Fig25:  In-vitro dissolution profile of F7 to F9 formulations. 
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 In-vitro dissolution studies were performed for all the formulations using USP dissolution 
apparatus II at 50 rpm using 900 ml of 0.1N HCl as dissolution medium. The samples 
withdrawn and were analyzed by using UV spectrophotometer. The drug release from the 
formulations F1-F3 prepared with Carbopol 934P was found to be 96.53, 93.11 and 
88.33%,  formulations F7-F9 prepared with HPMCK100M was found to be 98.74, 98.34, 
90.07% showed reasonable drug release, where as formulation F4- F6 prepared with 
Xanthan gum was found to be 96.94, 97.61, 96.13 at the end of 8 hours. As per the results 
of dissolution study the formulations F1-F9 the drug release was sustained for 8 to 12hr. 
 All the formulations were designed as dosage form for 12 hours.  In order to check the 
100% dissolution release profile, formulations were subjected to dissolution studies for 
12 hours. Among the nine formulations F8 was best and shows 98.34% drug release in 
the end of 12 hours. 
 It is evident from the in-vitro dissolution data that increase in HPMC K100M 
concentration decreases  the release rate this might be due to increase in diffusional path 
length, which the drug molecule may have to travel. . So, formulation F8 was selected as 
the optimized formulation. The results are shown in table no.17. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
RESULTS AND DISCUSSION 
 
Department of Pharmaceutics, Nandha College of Pharmacy. Page 61 
 
6.8 RELEASE KINETICS: 
Table No. 18 Model fitting for formulation F-8 
 
Time in 
hrs. 
 
% release 
 
Log % un-  
release 
 
Log t 
 
SQRT 
 
Log Cum 
%CDR 
0 0 2 0 0 0 
1 22.43 1.91 1 1 1.33 
2 31.11 1.83 0.30103 1.414214 1.49 
4 53.67 1.67 0.47712 1.73205 1.72 
6 65.28 1.54 0.60206 2 1.81 
8 76.59 1.38 0.69897 2.23606 1.88 
10 88.76 0.77 0.778155 2.44949 1.94 
12 98.34 0.29 0.845098 2.64575 1.99 
 
 
 
 
 
                                  Fig26:   Zero order kinetic model of F1 F2 F3 
 
0 
20 
40 
60 
80 
100 
120 
0 5 10 15 
cu
m
u
la
ti
ve
 %
d
ru
g 
re
le
as
e
 
time in hrs 
F1 
F2 
F3 
RESULTS AND DISCUSSION 
 
Department of Pharmaceutics, Nandha College of Pharmacy. Page 62 
 
 
                                   Fig27:  Zero order kinetic model of F4 F5 F6 
 
 
                                Fig28:  Zero order kinetic model of F7 F8 F9    
   
 
Fig29: First order kinetic model of F1 F2 F3 
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                                 Fig30: First order kinetic model of F4 F5 F6 
 
 
                                 Fig31: First order kinetic model of F7 F8 F9 
 
 
                                         Fig32: Higuchi model of F1, F2, F3 
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Fig33: Higuchi model of F4, F5, F6 
 
 
Fig34: Higuchi model of F7, F8, F9 
 
 
 
Fig35: Peppas model of F1, F2, F3 
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Fig36: Peppas model of F4, F5, F6 
 
 
 
Fig37: Peppas model of F7, F8, F9 
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Table No. 19 Correlation coefficients of different mathematical models for  F-1 to F-9 
 
FORMULATION 
 
ZERO ORDER 
R
2
 
 
FIRST ORDER 
R
2
 
 
HIGUCHI 
R
2
 
 
PEPPAS 
R
2
 n value 
F1 0.891 0.938 0.961 0.964 0.612 
F2 0.912 0.947 0.984 0.972 0.579 
F3 0.934 0.979 0.987 0.987 0.586 
F4 0.830 0.872 0.857 0.878 0.457 
F5 0.886 0.907 0.893 0.885 0.466 
F6 0.898 0.926 0.935 0.959 0.569 
F7 0.925 0.947 0.990 0.985 0.669 
F8 0.959 0.953 0.998 0.987 0.660 
F9 0.974 0.958 0.995 0.982 0.716 
 
 The in-vitro drug release data of the floating tablets were evaluated kinetically by zero 
order kinetics; first order kinetics, Higuchi plot and Peppa’s models. The regression 
coefficient (R2) value for Zero order, First order, Higuchi’s, and Peppa’s plots for 
optimized formulation F8 was found to be 0.959, 0.953, 0.998, 0.987.The optimized 
formulation F8 follows Higuchi’s plot since the regression coefficient is 0.998 also plots 
were found to be linear, which indicates that the drug release depended on the square 
root of the time and predominantly controlled by diffusion process. 
 
 The mechanism of drug release is predicted by using Korsmeyer–Peppas equation. The n 
value of optimized formulation F8 is 0.66 respectively and is between “0.45 to 0.85”. 
This indicates that the drug release depends on swelling, diffusion, and erosion. All 
formulations follow the non-Fickian/anomalous type of diffusion. 
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6.9 STABILITY STUDIES: 
Table no. 20: Stability studies of optimized formulation F8 
 
Time( days) 
25
o
C ± 2
o
C/60% RH ± 5% RH, 30
o
C ± 2
o
C/65% RH ± 5% RH,  40
o
C ± 2
o
C/75% RH ± 5% 
RH 
Hardness(kg/cm
2
) Drug content (%) %  Drug release  Total floating time 
30 5.56 98.45 98.34 >12 
60 5.56 98.42 98.27 >12 
90 5.48 98.18 98.71 >12 
 
 
 Stability studies were carried out on selected formulations (F8) as per ICH guidelines. 
There was not much variation in matrix integrity of the tablets at all the temperature 
conditions. There was no significant changes in drug content, physical stability, hardness, 
friability, drug release, floating lag time (Table 20) for the selected formulation F8 after 
90 days at 25
o
C± 2
0
C / 60% ± 5% RH, 30
0
C ± 2
0
C / 65% ±5% RH and 40
0
C ± 2
0
 / 75% ± 
5% RH. 
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6.10 COMPARISON WITH MARKETED PRODUCT:     
Table no.21: Comparative studies with optimized formulation 
Time(hrs) Cumulative % drug release 
F8 Marketed product 
1 22.42 27.64 
2 31.11 37.18 
4 53.67 56.79 
6 65.28 74.28 
8 76.59 92.08 
10 88.76 96.16 
12 98.34 96.87 
                                  
 
 
Fig38: Plot of comparative dissolution profile of optimized formulation (F8) and Marketed 
product 
 The marketed product releases 96.16% drug in 10 hrs where as the optimized formulation 
F8 releases 98.3% of drug in 12 hrs. Thus comparison study of the marketed product of 
Venlafaxine HCl showed that the optimized formulation F8 has better control over 
release rate in comparison to the commercial product.  
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7. SUMMARY AND CONCLUSION 
 
Floating Drug Delivery System are retained in the stomach for a longer time and assist in 
improving the oral controlled delivery of drugs that have an absorption window in the particular 
region of the GI tract as well as for controlling the release of the drug having site-specific 
absorption limitation.  
 
Venlafaxine HCl is a highly effective antidepressant was used as a model drug to develop 
a controlled release formulation. Venlafaxine HCl exhibits pH dependent solubility. It is more 
soluble in acidic pH and slightly soluble at neutral or alkaline condition (intestinal environment). 
Hence an attempt was made to develop gastroretentive delivery system of Venlafaxine HCl 
which increased the bioavailability of Venlafaxine HCl and also to reduce frequency of 
administration, thereby improving patient compliance and therapeutic efficacy.  
 
In the present work, 9 different formulations were prepared by direct compression, 
incorporating polymers like Carbopol934, Xanthan gum and HPMC K100M as swelling 
polymers, sodium bicarbonate as gas generating agent, MCC as a diluents, talc used as glidant 
and magnesium stearate used as lubricant.  
  
Characterization of the drug was done by performing the UV spectroscopy and IR 
spectroscopy. IR spectrum of the pure drug was compared with that of physical mixture of drug 
with all the excipients used in the study. The results showed that there was no drug-excipient 
interaction. The UV spectral analysis of the drug solution indicated that λmax value as 224 nm. 
 
All the prepared floating formulations were evaluated for hardness, friability, uniformity 
of weight, drug content uniformity, drug-polymer interaction, in-vitro floating studies, in vitro 
drug release and short term stability studies.  
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The thickness of the formulations (F1-F9) was in the range of 3.62 + 0.03 to    3.71 + 
0.05mm and the hardness was in the range of 5.3 + 0.2 to 6.1 + 0.3 Kg/ cm
2
, indicated good 
mechanical strength of the tablets. Friability, weight variation and drug content uniformity was 
found to be within official limits for all the formulations.  
 
The dissolution studies were carried out for 12 hrs. As per the result of dissolution study 
formulationF1, F2, F7, and F8 showed reasonable release respectively. But F8 showed good 
floating lag time and total floating time, when compare to other formulations. Based on all these 
results, formulation F8 was selected as the optimized formulation. F8 was then compared to the 
marketed product and was found that the optimized formulation F8 has better control over 
release rate in comparison to the commercial product. 
 
 The release kinetics were fitted to different mathematical models like Zero order, First 
order, Higuchi’s and Peppa’s plot. The selected formulation F8 follows Higuchi’s plot and slope 
(n) value of Peppa’s for these formulations were found to be in the range of “0.45 to 0.85”. This 
indicates that the drug release depends on swelling, erosion, and diffusion. Thus follows the non-
Fickian/anomalous type of diffusion. 
 
The drug-polymer ratios, viscosity of polymers, were found to influence the drug release 
and floating properties of the prepared tablets. From the results it can be concluded that as the 
concentration of the polymer increased floating lag time decreased and the percentage drug 
release was prolonged. Viscosity of the polymer also showed a directly proportional relationship 
with swelling characteristics of the tablets. 
 
        The optimized formulation (F8) was subjected for stability studies as per ICH guidelines. 
Formulations subjected for short term stability studies were checked for drug content, hardness, 
friability and Total floating time for 90 days with an interval of 15 days. The formulations were 
found to be stable as no significant change was observed in the various evaluated parameters of 
the formulations. 
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